{"id":514637,"date":"2020-10-30T19:40:01","date_gmt":"2020-10-30T19:40:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=514637"},"modified":"2020-10-30T19:40:01","modified_gmt":"2020-10-30T19:40:01","slug":"global-arthritis-monoclonal-antibodies-mabs-market-value-expected-to-reach-5605-billion-by-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-arthritis-monoclonal-antibodies-mabs-market-value-expected-to-reach-5605-billion-by-2023_514637.html","title":{"rendered":"Global Arthritis Monoclonal Antibodies (mabs) Market Value Expected To Reach $56.05 Billion By 2023"},"content":{"rendered":"
\"Global<\/a><\/p>\n
\n
Arthritis Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change<\/div>\n<\/div>\n<\/div>\n
Johnson & Johnson Is One Of The Largest Players In The Arthritis Monoclonal Antibodies (mabs) Market, According To The Business Research Company\u2019s Arthritis Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change<\/div>\n

(Companies Covered: Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC, Mylan N.V, Bristol Myers Squibb, Eli Lily and Company, Thermofischer Scientific)<\/em><\/p>\n

The global arthritis monoclonal antibodies market is expected to decline from $46.48 billion in 2019 to $45.18 billion in 2020 at a compound annual growth rate of -2.8%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $56.05 billion in 2023 at a compound annual growth rate of 7.45%. <\/p>\n

Read More On The Global Arthritis Monoclonal Antibodies (mabs) Market Report At –
<\/strong>https:\/\/www.thebusinessresearchcompany.com\/report\/arthritis-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change<\/a><\/p>\n

The arthritis monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of arthritis diseases. Arthritis is referred to as the joint pain that is characterized by inflammation, tenderness, pain and stiffness in and around the joints. Different monoclonal antibody drugs are used for the treatment of arthritis. These include infliximab, adalimumab and golimumab. The market consists of revenue generated by the companies manufacturing monoclonal antibody drugs for arthritis by the sales of these products. <\/p>\n

Global Arthritis Monoclonal Antibodies (mabs) Market Segmentation – <\/strong>
1) By Drug:<\/strong> Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima.
2) By Application:<\/strong> Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Others. <\/p>\n

Global Arthritis Monoclonal Antibodies (mabs) Market Driver – <\/strong>
The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market.<\/p>\n

Request For A Sample Of The Global Arthritis Monoclonal Antibodies (mabs) Market Report At – <\/strong>
https:\/\/www.thebusinessresearchcompany.com\/sample.aspx?id=3449&type=smp<\/a><\/p>\n

Few Points From The Global Arthritis Monoclonal Antibodies (mabs) Market TOC<\/strong>
1. Executive Summary
2. Arthritis Monoclonal Antibodies (mabs) Market Characteristics
3. Arthritis Monoclonal Antibodies (mabs) Market Size And Growth
3.1. Global Arthritis Monoclonal Antibodies (mabs) Historic Market, 2015 – 2019, $ Billion
4. Arthritis Monoclonal Antibodies (mabs) Market Segmentation
4.1. Global Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Arthritis Monoclonal Antibodies (mabs) Market Regional And Country Analysis
5.1. Global Arthritis Monoclonal Antibodies (mabs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6. Asia-Pacific Arthritis Monoclonal Antibodies (mabs) Market
6.1. Asia-Pacific Arthritis Monoclonal Antibodies (mabs) Market Overview
6.2. Asia-Pacific Arthritis Monoclonal Antibodies (mabs) Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion<\/p>\n

Interested to know more about The Business Research Company? <\/strong><\/p>\n

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Business Research Company<\/a>
Contact Person:<\/strong> Oliver Guirdham
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +44 20 7193 0708
Address:<\/strong>
City:<\/strong> London
State:<\/strong> Greater London
Country:<\/strong> United Kingdom
Website:<\/strong> https:\/\/www.thebusinessresearchcompany.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Arthritis Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change Johnson & Johnson Is One Of The Largest Players In The Arthritis Monoclonal Antibodies (mabs) Market, According To The Business Research Company\u2019s Arthritis Monoclonal Antibodies Global Market Report 2020-30: … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-514637","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/514637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=514637"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/514637\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=514637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=514637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=514637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}